In 2021, $NIO peaked above $100B market cap. Then came four brutal years. Fast forward to 2026: → Deliveries up 96% YoY in January → First operating profit ever on the horizon → Battery swap tech reaching mainstream scale The comeback will be incredible!

The part that matters in Oscar Health $OSCR isn’t the noise in any one quarter—it’s the forward targets they’re willing to publish. For 2026 they guided $18.7–$19.0B revenue and $250–$450M “earnings from operations,” which is a very different setup than “maybe someday

Most people are sleeping on $NIO in 2026. It seems to be one of the most asymmetric EV plays right now: → 1M+ cumulative deliveries ✅ → First-ever adjusted operating profit (Q4 2025) ✅ → 5th-gen battery swap stations going live ✅ → 3-brand architecture unlocking new

What should my next article be about? Drop your suggestions in the comments. A few, I am interested in are: $NIO battery swapping, $XPEV deep dive, $NVO deep dive

As oil prices rise amid escalating geopolitical tensions, $NIO's electric vehicle ecosystem is primed for heightened demand. Its proprietary battery-swapping infrastructure delivers substantial cost efficiencies and reduced downtime, appealing to consumers shifting from

If you're searching for something to read over the weekend, I can recommend my deep dive article about $NIO!

$NIO has achieved over 102 million battery swaps, underscoring the scalability of its Power Swap technology. A full battery replacement takes approximately 3 minutes, supported by more than 3,750 swap stations globally and over 2,100 patents in energy infrastructure. This has

$NIO delivered 47,979 vehicles in the first two months of 2026 — up 77.3% YoY. Q4 2025 earnings drop on March 10, with its first-ever adjusted operating profit projected ($100M–$172M). The inflection point isn't coming. It's here. 📈

Oscar Health $OSCR is writing one of the most compelling turnaround stories in healthcare. Revenue: $463M in 2020 → $11.7B in 2025 → guiding $18.7–$19.0B in 2026. That's not a company. That's a rocket. 🚀

$NIO: +96.1% YoY deliveries in January, +57.6% in February. Q4 2025 first-ever operating profit incoming. 5 new models launching in 2026. 40–50% volume growth targeted. Anyone still calling this a broken story isn't watching the data.

$OSCR in 2026: → Revenue nearly doubling YoY → Membership hits 3.4M → Market share 30% → First profitable year incoming This is not a small-cap speculative bet, this is the future of individual healthcare insurance!

$NIO in 2026: ✅ 1M+ cumulative deliveries ✅ First-ever adjusted operating profit ✅ 77.3% YTD delivery growth ✅ 5 new models incoming ✅ Morgan Stanley, Goldman, UBS all bullish The narrative has flipped. Size your position accordingly.

Most people will probably find out about $NIO after the earnings! You have until tomorrow, March 10. 👀 #NIO #EV

If you want to read a deep dive about $NIO before tomorrow's earnings: x.com/InvestorSince2…

The chart of $NIO has not changed since the last update. It tested the 0.5 Fibonacci level and was rejected. Right now it is testing it again. If tomorrow’s earnings are great, I expect it to convert this level without issue. If the earnings (especially the guidance) are not

I’m really looking forward to tomorrow. $NIO's earnings are going to be very interesting!

Do you want a UnitedHealth $UNH chart?

Novo Nordisk $NVO's quiet comeback gains traction with the $Hims tie-up, alleviating legal risks and enhancing telehealth access for key drugs. Trading at a P/E of 11x—well below averages—with projected long-term EPS growth and FDA support against rivals, Novo Nordisk is primed